Solvonis Therapeutics plc
SVNS.L · LSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | £0 | £587 | £542 | £219 |
| % Growth | -100% | 8.3% | 147.5% | – |
| Cost of Goods Sold | £0 | £446 | £593 | £164 |
| Gross Profit | £0 | -£134 | -£51 | £55 |
| % Margin | – | -22.8% | -9.4% | 25.1% |
| R&D Expenses | £0 | £0 | £0 | £0 |
| G&A Expenses | £796 | £677 | £2,667 | £1,543 |
| SG&A Expenses | £796 | £2,076 | £2,657 | £900 |
| Sales & Mktg Exp. | £0 | £1,399 | -£10 | -£643 |
| Other Operating Expenses | £587 | £0 | £0 | £0 |
| Operating Expenses | £1,383 | £3,258 | £2,657 | £900 |
| Operating Income | -£1,383 | -£3,117 | -£2,708 | -£845 |
| % Margin | – | -531% | -499.6% | -385.8% |
| Other Income/Exp. Net | -£64 | -£3 | -£4 | -£109 |
| Pre-Tax Income | -£1,447 | -£3,120 | -£2,705 | -£954 |
| Tax Expense | £0 | £0 | £0 | £0 |
| Net Income | -£1,590 | -£3,120 | -£2,705 | -£954 |
| % Margin | – | -531.5% | -499.1% | -435.6% |
| EPS | -0.001 | -0.03 | -0.026 | -0.009 |
| % Growth | 96% | -14.9% | -183.7% | – |
| EPS Diluted | -0.001 | -0.03 | -0.026 | -0.009 |
| Weighted Avg Shares Out | 1,156,732 | 104,057 | 103,589 | 104,097 |
| Weighted Avg Shares Out Dil | 1,156,732 | 104,057 | 103,589 | 104,097 |
| Supplemental Information | – | – | – | – |
| Interest Income | £0 | £0 | £0 | £14 |
| Interest Expense | £64 | £3 | £4 | £8 |
| Depreciation & Amortization | £0 | £177 | £113 | £46 |
| EBITDA | -£1,383 | -£2,938 | -£2,588 | -£900 |
| % Margin | – | -500.5% | -477.5% | -411% |